e-learning
resources
Vienna 2012
Tuesday, 04.09.2012
Epidemiology of asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Characteristics of the uncontrolled asthmatic patients on GINA step 4 treatment in Korea
K.H. Yoo, K.S. Jung, Y.I. Hwang, Y.B. Park, S.Y. Lee, S.H. Jang, J.H. Kim, D.G. Kim, Y.D. Lee (Seoul, Pyung Chon, Republic Of Korea)
Source:
Annual Congress 2012 - Epidemiology of asthma
Session:
Epidemiology of asthma
Session type:
Thematic Poster Session
Number:
3952
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K.H. Yoo, K.S. Jung, Y.I. Hwang, Y.B. Park, S.Y. Lee, S.H. Jang, J.H. Kim, D.G. Kim, Y.D. Lee (Seoul, Pyung Chon, Republic Of Korea). Characteristics of the uncontrolled asthmatic patients on GINA step 4 treatment in Korea. Eur Respir J 2012; 40: Suppl. 56, 3952
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Lung function in epidemiological studies from infancy to childhood with focus on urban environment
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
Efficacy of omalizumab in patients with moderate-to-severe allergic asthma that is poorly controlled on GINA (1998) treatment step 3 or 4
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003
Characterization of adults with asthma per GINA treatment steps
Source: International Congress 2019 – Epidemiology, genetics, air pollution and sleep
Year: 2019
Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials
Source: International Congress 2016 – Asthma management
Year: 2016
SQ HDM SLIT-tablet is effective in patients not well-controlled in GINA treatment steps 2-4
Source: International Congress 2016 – Asthma management
Year: 2016
Asthma control and exacerbation rate with omalizumab in Italian patients with severe allergic asthma: PROXIMA study
Source: International Congress 2017 – Asthma management
Year: 2017
BTS Difficult Asthma Registry: Effect of omalizumab dosing table expansion on size of population of severe persistent allergic asthma patients potentially eligible for omalizumab therapy
Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma
Year: 2012
10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab.
Source: International Congress 2018 – Physiological and biological insights in asthma
Year: 2018
The application of GINA guidelines results in a reduced number of exacerbations in asthmatic patients
Source: Annual Congress 2009 - Quality of treatment in primary respiratory care
Year: 2009
Effect of allergic sensitization on clinical course of patients with COPD in the Hokkaido COPD cohort study
Source: International Congress 2014 – COPD physiopathology
Year: 2014
Outcomes with omalizumab in Indian patients with allergic (IgE-mediated) asthma: Results at 16 and 28 weeks
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Effect of tralokinumab on GINA control in severe, uncontrolled asthma
Source: International Congress 2017 – Asthma: mechanisms and treatment
Year: 2017
Asthma control is reached in a large majority of asthmatics treated with omalizumab. An Italian observational study
Source: Annual Congress 2013 –Disease control and quality of life in airway diseases
Year: 2013
Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy
Source: ERJ Open Res, 3 (3) 00004-2017; 10.1183/23120541.00004-2017
Year: 2017
Uncontrolled asthma on GINA step 4-5 treatment increases healthcare utilization – report from the population-based OLIN-studies
Source: International Congress 2019 – Nursing care across the spectrum of respiratory illnesses
Year: 2019
P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients
Source: International Congress 2016 – Asthma management
Year: 2016
Asthma control test (ACT) in outpatients and hospitalized patients with bronchial asthma
Source: Annual Congress 2009 - Asthma and comorbid conditions
Year: 2009
Asthma control with omalizumab treatment in severe allergic asthma and severe non-allergic asthma patients
Source: International Congress 2015 – Asthma and lung immunology
Year: 2015
The parameters that may affect inhalation therapy success in elderly COPD and asthma patients
Source: International Congress 2015 – Co-existing diseases and asthma
Year: 2015
‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study
Source: Annual Congress 2011 - Asthma management and response
Year: 2011
Clinical profile and treatment of elderly patients hospitalized for acute exacerbation of asthma . A comparative study
Source: International Congress 2014 – Asthma: clinical problems
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept